Effects of short-term overfeeding with fructose, fat and fructose plus fat on plasma and hepatic lipids in healthy men

The present study aimed to assess the effects of excess fat, fructose and fat-plus-fructose intakes on intrahepatocellular lipid (IHCL).

Exercise and spirulina control non-alcoholic hepatic steatosis and lipid profile in diabetic Wistar rats

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

JTT-130, a Microsomal Triglyceride Transfer Protein (MTP) Inhibitor Lowers Plasma Triglycerides and LDL Cholesterol Concentrations without Increasing Hepatic Triglycerides in Guinea Pigs

BACKGROUND: Microsomal transfer protein inhibitors (MTPi) have the potential to be used as a drug to lower plasma lipids, mainly plasma triglycerides (TG). However, studies with animal models have indicated that MTPi treatment results in the accumulation of hepatic TG. The purpose of this study was to evaluate whether JTT-130, a unique MTPi, targeted to the intestine, would effectively reduce plasma lipids without inducing a fatty liver. METHODS: Male guinea pigs (n = 10 per group) were used for this experiment. Initially all guinea pigs were fed a hypercholesterolemic diet containing 0.08 g/100 g dietary cholesterol for 3 wk. After this period, animals were randomly assigned to diets containing 0 (control), 0.0005 or 0.0015 g/100 g of MTPi for 4 wk. A diet containing 0.05 g/100 g of atorvastatin, an HMG-CoA reductase inhibitor was used as the positive control. At the end of the 7th week, guinea pigs were sacrificed to assess drug effects on plasma and hepatic lipids, composition of LDL and VLDL, hepatic cholesterol and lipoprotein metabolism. RESULTS: Plasma LDL cholesterol and TG were 25 and 30% lower in guinea pigs treated with MTPi compared to controls (P < 0.05). Atorvastatin had the most pronounced hypolipidemic effects with a 35% reduction in LDL cholesterol and 40% reduction in TG. JTT-130 did not induce hepatic lipid accumulation compared to controls. Cholesteryl ester transfer protein (CETP) activity was reduced in a dose dependent manner by increasing doses of MTPi and guinea pigs treated with atorvastatin had the lowest CETP activity (P < 0.01). In addition the number of molecules of cholesteryl ester in LDL and LDL diameter were lower in guinea pigs treated with atorvastatin. In contrast, hepatic enzymes involved in maintaining cholesterol homeostasis were not affected by drug treatment. CONCLUSION: These results suggest that JTT-130 could have potential clinical applications due to its plasma lipid lowering effects with no alterations in hepatic lipid concentrations.

β-Lapachone alleviates alcoholic fatty liver disease in rats

Alcohol-induced liver injury is the most common liver disease in which fatty acid metabolism is altered. It is thought that altered NAD+/NADH redox potential by alcohol in the liver causes fatty liver by inhibiting fatty acid oxidation and the activity of tricarboxylic acid cycle reactions. β-Lapachone (βL), a naturally occurring quinone, has been shown to stimulate fatty acid oxidation in an obese mouse model by activating adenosine monophosphate-activated protein kinase (AMPK). In this report, we clearly show that βL reduced alcohol-induced hepatic steatosis and induced fatty acid oxidizing capacity in ethanol-fed rats. βL treatment markedly decreased hepatic lipids while serum levels of lipids and lipoproteins were increased in rats fed ethanol-containing liquid diets with βL administration. Furthermore, inhibition of lipolysis, enhancement of lipid mobilization to mitochondria and upregulation of mitochondrial β-oxidation activity in the soleus muscle were observed in ethanol/βL-treated animals compared to the ethanol-fed rats. In addition, the activity of alcohol dehydrogenase, but not aldehyde dehydrogenase, was significantly increased in rats fed βL diets. βL-mediated modulation of NAD+/NADH ratio led to the activation of AMPK signaling in these animals. Conclusion: Our results suggest that improvement of fatty liver by βL administration is mediated by the upregulation of apoB100 synthesis and lipid mobilization from the liver as well as the direct involvement of βL on NAD+/NADH ratio changes, resulting in the activation of AMPK signaling and PPARα-mediated β-oxidation. Therefore, βL-mediated alteration of NAD+/NADH redox potential may be of potential therapeutic benefit in the clinical setting.

Le rôle de la dysrégulation du métabolisme du cholestérol par le retrait des estrogènes sur la stéatose hépatique

Les estrogènes confèrent aux femmes une protection cardiovasculaire jusqu’à la ménopause. En effet, la perte des fonctions ovariennes engendre plusieurs désordres du profil lipidique qui s’accompagnent d’une accumulation de triglycérides au foie appelée stéatose hépatique. Le retrait des estrogènes perturbe de nombreuses voies de contrôle de la cholestérolémie, provoquant simultanément une hypercholestérolémie et une stéatose hépatiques. Toutefois, à ce jour, les mécanismes d’action du retrait des estrogènes sur le métabolisme du cholestérol favorisant le stockage de triglycérides au foie demeurent imprécis. À cet égard, les travaux de cette thèse visaient à clarifier l’ensemble des effets du retrait des estrogènes sur le métabolisme du cholestérol pouvant mener à la pathogenèse de la stéatose hépatique. Lors de la première étude, l’ovariectomie (Ovx) chez la rate, un modèle bien établi de la stéatose, avait permis d’identifier la voie d’assemblage des lipoprotéines à très faible densité (VLDL) comme élément contributif à la stéatose. La voie des VLDL reliant étant également une voie de transport du cholestérol, l’étude suivante a été réalisée afin de comprendre le rôle du cholestérol alimentaire sur les lipides hépatiques. Dans cette deuxième étude, le modèle de la diète riche en lipides et en cholestérol (HFHC), aussi reconnu pour induire une stéatose hépatique, a permis d’établir des liens étroits entre le métabolisme du cholestérol et celui des lipides hépatiques. Étonnamment, de manière similaire à l’Ovx, la diète HFHC perturbait la voie d’assemblage des VLDL. En outre, les données recueillies au cours de ces travaux indiquaient qu’une dysrégulation du métabolisme des acides biliaires avait contribué à la sévérité de la stéatose hépatique induite par cette diète HFHC. Dans la continuité de ces deux premiers projets, nous nous sommes intéressés aux effets concomitants du retrait des estrogènes et d’une diète HFHC sur la stéatose hépatique. De manière intéressante, lorsque combinés, l’Ovx et la diète HFHC potentialisaient non seulement l’accumulation de lipides hépatiques, mais également les perturbations moléculaires des voies sous-jacentes à la stéatose, dont l’assemblage des VLDL et de la sécrétion d’acides biliaires. Dans l’ensemble, les données présentées dans la revue de littérature et dans les trois études reliées à cette thèse indiquent qu’une dysrégulation du métabolisme du cholestérol en réponse au retrait des estrogènes entraîne des complications favorisant l’accumulation de lipides dans le foie.

Le rôle du stress oxydant dans les changements épigénétiques contribuant aux complications du syndrome métabolique.

La méthylation de l'ADN est l'une des modifications épigénétiques au niveau des îlots CpG. Cette modification épigénétique catalysée par les ADN méthyltransférases (DNMTs) consiste en la méthylation du carbone 5' d’une cytosine ce qui aboutit à la formation de 5-méthylcytosine. La méthylation de l'ADN est clairement impliquée dans l'inactivation des gènes et dans l'empreinte génétique. Elle est modulée par la nutrition, en particulier par les donneurs de méthyle et par une restriction protéique. Ces modifications épigénétiques persistent plus tard dans la vie et conduisent au développement de nombreuses pathologies telles que le syndrome métabolique et le diabète de type 2. En fait, de nombreux gènes clés subissent une modification de leur état de méthylation en présence des composants du syndrome métabolique. Cela montre que la méthylation de l'ADN est un processus important dans l'étiologie du syndrome métabolique. Le premier travail de ce doctorat a porté sur la rédaction d’un article de revue qui a examiné le cadre central du syndrome métabolique et analyser le rôle des modifications épigénétiques susceptibles d'influer sur l'apparition du stress oxydant et des complications cardiométaboliques. D’autre part, les cellules intestinales Caco-2/15, qui ont la capacité de se différencier et d’acquérir les caractéristiques physiologiques de l'intestin grêle, ont été utilisées et traitées avec du Fer-Ascorbate pour induire un stress oxydant. Le Fer-Ascorbate a induit une augmentation significative de l’inflammation et de la peroxydation des lipides (malondialdehyde) ainsi que des altérations de de la défense antioxydante (SOD2 et GPx) accompagnées de modifications épigénétiques. De plus, la pré-incubation des cellules avec de la 5-aza-2'-désoxycytidine, un agent de déméthylation et/ou l’antioxydant Trolox a normalisé la défense antioxydante, réduit la peroxydation des lipides et prévenu l'inflammation. Ce premier travail a démontré que les modifications du redox et l’inflammation induites par le Fer-Ascorbate peuvent impliquer des changements épigénétiques, plus particulièrement des changements dans la méthylation de l’ADN. Pour mieux définir l’impact du stress oxydant au niveau nutritionnel, des cochons d’Inde âgés de trois jours ont été séparés en trois groupes : 1) Témoins: alimentation régulière; 2) Nutrition parentérale (NP) 3) H2O2 : Témoins + 350 uM H2O2. Après quatre jours, pour un groupe, les perfusions ont été stoppées et les animaux sacrifiés pour la collecte des foies. Pour l’autre groupe d’animaux, les perfusions ont été arrêtées et les animaux ont eu un accès libre à une alimentation régulière jusqu'à la fin de l’étude, huit semaines plus tard où ils ont été sacrifiés pour la collecte des foies. Ceci a démontré qu’à une semaine de vie, l'activité DNMT et les niveaux de 5'-méthyl-2'-désoxycytidine étaient inférieurs pour les groupes NP et H2O2 par rapport aux témoins. A neuf semaines de vie, l’activité DNMT est restée basse pour le groupe NP alors que les niveaux de 5'-méthyl-2'-désoxycytidine étaient plus faibles pour les groupes NP et H2O2 par rapport aux témoins. Ce travail a démontré que l'administration de NP ou de H2O2, tôt dans la vie, induit une hypométhylation de l'ADN persistante en raison d'une inhibition de l'activité DNMT. Finalement, des souris ayant reçu une diète riche en gras et en sucre (HFHS) ont été utilisées comme modèle in vivo de syndrome métabolique. Les souris ont été nourris soit avec un régime standard chow (témoins), soit avec une diète riche en gras et en sucre (HFHS) ou avec une diète HFHS en combinaison avec du GFT505 (30 mg/kg), un double agoniste de PPARα et de PPARδ, pendant 12 semaines. La diète HFHS était efficace à induire un syndrome métabolique étant donnée l’augmentation du poids corporel, du poids hépatique, des adiposités viscérales et sous-cutanées, de l’insensibilité à l’insuline, des lipides plasmatiques et hépatiques, du stress oxydant et de l’inflammation au niveau du foie. Ces perturbations étaient accompagnées d’une déficience dans l’expression des gènes hépatiques PPARα et PPARγ concomitant avec une hyperméthylation de leurs promoteurs respectifs. L’ajout de GFT505 à la diète HFHS a empêché la plupart des effets cardiométaboliques induits par la diète HFHS via la modulation négative de l’hyperméthylation des promoteurs, résultant en l’augmentation de l’expression des gènes hépatiques PPARα et PPARγ. En conclusion, GFT505 exerce des effets métaboliques positifs en améliorant le syndrome métabolique induit par l'alimentation HFHS via des modifications épigénétiques des gènes PPARs. Ensemble, les travaux de cette thèse ont démontré que le stress oxydant provenant de la nutrition induit d’importants changements épigénétiques pouvant conduire au développement du syndrome métabolique. La nutrition apparait donc comme un facteur crucial dans la prévention de la reprogrammation fœtale et du développement du syndrome métabolique. Puisque les mécanismes suggèrent que le stress oxydant agit principalement sur les métabolites du cycle de la méthionine pour altérer l’épigénétique, une supplémentation en ces molécules ainsi qu’en antioxydants permettrait de restaurer l’équilibre redox et épigénétique.

The effects of stocking density in physiological parameters and growth of the endangered teleost species piabanha, Brycon insignis (Steindachner, 1877)

This study investigated the effects of stocking density on the growth and fatty acid (FA) of Brycon insignis metabolism. Fingerlings (360) were distributed into eight ponds at two stocking densities (105 and 210 g/m(3)). The analysis of growth showed that the condition factor (K) and the coefficient of variation (CV) for body mass were not affected by stocking density. However, final body mass and length, specific growth rate (SGR), and weight gain (WG) were higher in the low stocking density group, which also presented a higher feed efficiency (FE) and survival (S). By contrast, muscle protein levels were higher in the high stocking density group. The plasma and muscle lipid content were not affected by stocking density, but fish reared at lower stocking density presented higher lipid concentration in the liver, with no differences in hepatosomatic index values. Even with the differences observed in metabolic and growth parameters, plasma cortisol was not affected by stocking density. The FA profile in the muscle and liver neutral fraction were not affected by stocking density, but the FA in the polar fractions differed between the two stocking densities. In the liver, total polyunsaturated fatty acids (PUFA) and PUFA n - 3 increased in higher stocking density, mainly due to an increase in docosahexaenoic acid (DHA). In addition, PUFA n - 6 were also increased in the higher stocking density group, mainly due to an increase in arachidonic acid (AA) and docosadienoic acid (22:2n - 6). In the muscle polar fraction, the saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA) decreased in the animals from the higher stocking density group, and this reduction was compensated by an increase in PUFA n - 3 and PUFA n - 6, mainly the FA with 20-22 carbons (20:4n - 6: 22:4:n - 6; 22:5n - 6, 22:5n - 3, and 22:6n - 3). A different profile was observed for the C18 PUFAs, mainly 18:2n - 6 and 18:4n - 6, which were higher in the lower density stocking group. The data suggest that when living in high stocking density, B. insignis differentially utilizes the hepatic lipids as energy source and remodels the membrane fatty acids, with higher amounts of DHA in the polar muscle fraction compensated for by a decrease in MUFA. The zootechnical and physiological indices reveal that the lower stocking density group achieve overall better performance. (C) 2010 Elsevier B.V. All rights reserved.

Colina e betaína em rações purificadas na nutrição da tilápia do Nilo (Oreochromis niloticus)

Problemas metabólicos observados em produções intensivas de tilápias do Nilo (Oreochromis niloticus) têm sido relacionados à deficiência de colina nas rações. Com o objetivo de avaliar o efeito da suplementação dietética da colina na nutrição da espécie, rações purificadas contendo 0; 375; 750; 1.125; 1.500 ou 1.875 mg de cloreto de colina por kg, foram administradas ad libitum por 42 dias a tilápias do Nilo (5,09 ± 0,14 g), estocados em gaiolas de PVC atóxico (volume = 60 L), alojadas em caixas de polipropileno de 1000 L, em ambiente com condições controladas de temperatura e luminosidade, num delineamento experimental em blocos incompletos casualizados, com três parcelas por bloco (n=5). O ganho de peso (GDP) e o índice de conversão alimentar (ICA) de todos os tratamentos foram superiores ao controle. Não foram observadas diferenças para a quantidade de lipídios no fígado e tecido corporal, e sobrevivência (S%). Num segundo experimento, os peixes foram alimentados com rações suplementadas com 1.250 ou 2.500 mg de cloreto de colina por kg; ou 1.000; 2.000 ou 3.000 mg de betaína por kg. Não foram observadas diferenças significativas para S% e acúmulo de lipídeos hepáticos ou corporais; o ICA e GDP dos tratamentos suplementados com colina foram superiores aos dos tratamentos suplementados com betaína, mas não diferiram entre si. Níveis de suplementação superiores a 375 mg de cloreto de colina por kg de alimento melhoram o ICA e o GDP da tilápia do Nilo, mas a betaína não substitui efetivamente a colina em rações para a espécie.

Effects of dietary fatty acid composition on basal and hormonestimulated hepatic lipogenesis and on circulating lipids in the rat

Thirty male rats were randomly assigned to one of three dietary groups in which the source of dietary fat was either a mixed oil, maize oil or fish oil. Effects of dietary fatty acid composition on in virro rates of [U-'4C]glucose incorporation into hepatic total lipids and into hepatic triacylglycerol were measured under basal, insulin (4 nM)-, gastric inhibitory polypeptide (GIP; 6 mi)- and insulin + GIP (4 nM + 6 n ~ ) - stimulated conditions. Effects of the three diets on postprandial plasma triacylglycerol, cholesterol, insulin and GIP concentrations were also measured. The fish-oil diet decreased rates of basal glucose incorporation into hepatic total lipids (P < 0.05) and hepatic triacylglycerol (P < 0.01) compared with the mixed-oil diet. The presence of insulin + GIP in the incubation medium stimulated glucose incorporation into hepatic total lipids in the maize-oil (P < 0.01) and fish-oil groups (P < OW), as well as into hepatic triacylglycerol in the maize-oil group (P < 0.005). In addition, the fish-oil diet decreased postprandial plasma triacylglycerol levels compared with both other dietary groups (P < 0-05 both cases), and the mixed-oil diet markedly increased postprandial plasma insulin levels compared with the other dietary groups (P c 0.001).

Effects of fructose and glucose overfeeding on hepatic insulin sensitivity and intrahepatic lipids in healthy humans

To assess how intrahepatic fat and insulin resistance relate to daily fructose and energy intake during short-term overfeeding in healthy subjects.

Regulation of hepatic cholesterolgenesis by ubiquinone

The concentration of liver ubiquinone increased progressively with the time of feeding ubiquinone, and this increase was reflected in all the cell fractions. 2. 2. Inhibition of sterol synthesis by ubiquinone was exerted only in the liver, not in the kidney or intestine. 3. 3. Extending the period of feeding ubiquinone or increasing the concentration of ubiquinone fed had no effect on the extent of inhibition. 4. 4. Inhibition was found to be specific to ubiquinone-9, the natural major homologue in the rat liver; other homologues were ineffective. 5. 5. The site of inhibition by ubiquinone was indicated to be between acetyl-CoA and mevalonate, since there was no change in fatty acid and ketone body synthesis in ubiquinone-fed animals as compared to normal animals.

The E2F2 Transcription Factor Sustains Hepatic Glycerophospholipid Homeostasis in Mice

Increasing evidence links metabolic signals to cell proliferation, but the molecular wiring that connects the two core machineries remains largely unknown. E2Fs are master regulators of cellular proliferation. We have recently shown that E2F2 activity facilitates the completion of liver regeneration after partial hepatectomy (PH) by regulating the expression of genes required for S-phase entry. Our study also revealed that E2F2 determines the duration of hepatectomy-induced hepatic steatosis. A transcriptomic analysis of normal adult liver identified "lipid metabolism regulation" as a major E2F2 functional target, suggesting that E2F2 has a role in lipid homeostasis. Here we use wild-type (E2F2(+/+)) and E2F2 deficient (E2F2(-/-)) mice to investigate the in vivo role of E2F2 in the composition of liver lipids and fatty acids in two metabolically different contexts: quiescence and 48-h post-PH, when cellular proliferation and anabolic demands are maximal. We show that liver regeneration is accompanied by large triglyceride and protein increases without changes in total phospholipids both in E2F2(+/+) and E2F2(-/-) mice. Remarkably, we found that the phenotype of quiescent liver tissue from E2F2(-/-) mice resembles the phenotype of proliferating E2F2(+/+) liver tissue, characterized by a decreased phosphatidylcholine to phosphatidylethanolamine ratio and a reprogramming of genes involved in generation of choline and ethanolamine derivatives. The diversity of fatty acids in total lipid, triglycerides and phospholipids was essentially preserved on E2F2 loss both in proliferating and non-proliferating liver tissue, although notable exceptions in inflammation-related fatty acids of defined phospholipid classes were detected. Overall, our results indicate that E2F2 activity sustains the hepatic homeostasis of major membrane glycerolipid components while it is dispensable for storage glycerolipid balance.

Novel equation to determine the hepatic triglyceride concentration in humans by MRI: diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgery

Background: Non-alcoholic fatty liver disease (NAFLD) is caused by abnormal accumulation of lipids within liver cells. Its prevalence is increasing in developed countries in association with obesity, and it represents a risk factor for non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Since NAFLD is usually asymptomatic at diagnosis, new non-invasive approaches are needed to determine the hepatic lipid content in terms of diagnosis, treatment and control of disease progression. Here, we investigated the potential of magnetic resonance imaging (MRI) to quantitate and monitor the hepatic triglyceride concentration in humans. Methods: A prospective study of diagnostic accuracy was conducted among 129 consecutive adult patients (97 obesity and 32 non-obese) to compare multi-echo MRI fat fraction, grade of steatosis estimated by histopathology, and biochemical measurement of hepatic triglyceride concentration (that is, Folch value). Results: MRI fat fraction positively correlates with the grade of steatosis estimated on a 0 to 3 scale by histopathology. However, this correlation value was stronger when MRI fat fraction was linked to the Folch value, resulting in a novel equation to predict the hepatic triglyceride concentration (mg of triglycerides/g of liver tissue = 5.082 + (432.104 * multi-echo MRI fat fraction)). Validation of this formula in 31 additional patients (24 obese and 7 controls) resulted in robust correlation between the measured and estimated Folch values. Multivariate analysis showed that none of the variables investigated improves the Folch prediction capacity of the equation. Obese patients show increased steatosis compared to controls using MRI fat fraction and Folch value. Bariatric surgery improved MRI fat fraction values and the Folch value estimated in obese patients one year after surgery. Conclusions: Multi-echo MRI is an accurate approach to determine the hepatic lipid concentration by using our novel equation, representing an economic non-invasive method to diagnose and monitor steatosis in humans.

Induction of hepatic enzymes and oxidative stress in Chinese rare minnow (Gobiocypris rarus) exposed to waterborne hexabromocyclododecane (HBCDD)

The objective of this study was to evaluate the sub-lethal toxicity of hexabromocyclododecane (HBCDD) in fish. Adult Chinese rare minnows as in vivo models were exposed to waterborne HBCDD from 1 to 500 mu g/l for 14, 28 and 42 days. Hepatic CYP1A1 (ethoxyresorufin-O-deethylase, EROD) and CYP2B1 (pentaoxyresorufin-O-depentylase, PROD) activities were measured. At the same time, molecular biomarkers of oxidative stress were also assayed in the brain, including reactive oxygen species (ROS), lipid peroxidation products (thiobarbituric acid-reactive substances, TBARS), DNA damage and protein carbonyl, as well as superoxide dismutase (SOD) activity and glutathione (GSH) content. DNA damage was evaluated using the Comet assay on erythrocytes. Besides, the content of HBCDD in whole fish was determined after 42 days exposure. The results show that HBCDD could induce EROD and PROD at 500 mu g/l after 28 days exposure, and at 100 to 500 mu g/l after 42 days exposure (P < 0.05), respectively. ROS formation in fish brain was observed to be increased in both time- and dose-dependent manner due to HBCDD exposure. The significant increases in TBARS and protein carbonyl contents occurred in fish brain after 28 and 42 days exposure (P < 0.05). Significant DNA damage in erythrocytes by Comet assay was also found in the 100-500 mu g/l exposure groups (P < 0.05) after 42 days exposure. Moreover, significant depletion in brain GSH content occurred in all treated groups (P < 0.05) and apparent inhibition in SOD activity in brain was observed in the groups of 10-500 mu g/l concentrations during 42 days exposure. The results demonstrate that increasing duration of HBCDD exposure induced EROD and PROD activities, caused excess ROS formation, finally resulted in oxidative damage to lipids, proteins and DNA and decreased antioxidant capacities in fish. Chemical analysis of HBCDD in whole fish showed accumulation up to 654 mu g/g wet weight. (c) 2007 Elsevier B.V. All rights reserved.

Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice

The liver secretes triglyceride-rich VLDLs, and the triglycerides in these particles are taken up by peripheral tissues, mainly heart, skeletal muscle, and adipose tissue. Blocking hepatic VLDL secretion interferes with the delivery of liver-derived triglycerides to peripheral tissues and results in an accumulation of triglycerides in the liver. However, it is unclear how interfering with hepatic triglyceride secretion affects adiposity, muscle triglyceride stores, and insulin sensitivity. To explore these issues, we examined mice that cannot secrete VLDL [due to the absence of microsomal triglyceride transfer protein (Mttp) in the liver]. These mice exhibit markedly reduced levels of apolipoprotein B-100 in the plasma, along with reduced levels of triglycerides in the plasma. Despite the low plasma triglyceride levels, triglyceride levels in skeletal muscle were unaffected. Adiposity and adipose tissue triglyceride synthesis rates were also normal, and body weight curves were unaffected. Even though the blockade of VLDL secretion caused hepatic steatosis accompanied by increased ceramides and diacylglycerols in the liver, the mice exhibited normal glucose tolerance and were sensitive to insulin at the whole-body level, as judged by hyperinsulinemic euglycemic clamp studies. Normal hepatic glucose production and insulin signaling were also maintained in the fatty liver induced by Mttp deletion. Thus, blocking VLDL secretion causes hepatic steatosis without insulin resistance, and there is little effect on muscle triglyceride stores or adiposity